Shorter regimens for tuberculosis infection (TB) treatment of children are associated with increased completion rates and fewer adverse events than the traditional treatment of 9 months of daily isoniazid (9H), a recent study found. The retrospective cohort study included children aged 0 to 18 years from 2014 to 2017 and compared the frequency of completion and adverse events in children receiving 3 months of once-weekly isoniazid and rifapentine (3HP), 4 months of daily rifampin (4R), and 9H. Among the details:
- TB infection treatment was started in 667 children: 283 (42.4%) 3HP, 252 (37.8%) 9H, and 132 (19.8%) 4R.
- Only 52% of children receiving 9H via self-administered therapy (SAT) completed therapy.
- The highest completion rates were seen with 3HP (96.8%) and the lowest with 9H under SAT (52.6%)
- Adverse events were more common in the 9H group.
Cruz AT, Starke JR. Completion rate and safety of tuberculosis infection treatment with shorter regimens. [Published online ahead of print January 23, 2018]. Pediatrics. doi:10.1542/peds.2017-2838.
It is difficult to take medicine, especially when you feel well and the medications are for prevention of future morbidity. Standard therapy for the treatment of latent TB is a 9-month regimen of isoniazid. Even though the 9-month regimen is effective at decreasing the likelihood of developing active TB, this study and others show only about 50% of people complete a 9-month regimen of INH. As former Surgeon General C. Everett Koop once said, “Medicines don’t work in people who don’t take them.” The study above shows that a 3-month regimen of once-weekly isoniazid and rifapentine has much higher rate of completion. — Neil Skolnik, MD
This Week's Must Reads
HCV Screening in Children Exposed During Pregnancy, Pediatrics; ePub 2018 May 2; Chappell, et al
Clinical & Economic Burden of HBV & HCV Infection , PLoS One; ePub 2018 Apr 30; Park, et al
Knowledge of HCV Status & Drug Treatment Programs, PLoS One; ePub 2018 Apr 27; Fisher, et al
Is Gut Dysbiosis Associated with HCV Infection?, Clin Infect Dis; ePub 2018 May 1; Inoue, et al
HCV Infection & Treatment Among People in Prison, Int J Drug Policy; 2018 Apr 28; Kronfli, et al
Must Reads in Pulmonology
Occupational Cleaning & Lung Function Decline, Am J Respir Crit Care Med; ePub 2018 Feb 16; Svanes, et al
Should Patients with Syncope be Evaluated for PE?, JAMA Intern Med; ePub 2018 Jan 29; Costantino, et al
Are Shorter Regimens of TB Infection Tx Safe?, Pediatrics; ePub 2018 Jan 23; Cruz, et al
Assessing Mepolizumab for Eosinophilic COPD, N Engl J Med; ePub 2017 Oct 26; Pavord, et al
LAMA + LABA for Patients with Stable COPD, JAMA; 2017 Oct 3; Horita, Nagashima, et al